Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas

MONDAY, April 29, 2024 -- For patients with metastatic pheochromocytomas and paragangliomas (MPPGs), an antiangiogenic multi-tyrosine kinase inhibitor, cabozantinib, is promising, according to a study published online April 9 in The Lancet...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news